Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

FDA Grants Octapharma 7-Year Market Exclusivity for Octagam 10%

Michele B. Kaufman, PharmD, BCGP  |  September 15, 2021

The FDA has granted a seven-year marketing exclusivity for Octagam 10%, a 10% solution of a human intravenous immunoglobulin (IVIG) that treats adults with dermatomyositis.

Filed under:ConditionsDrug UpdatesMyositis Tagged with:dermatomyositisdermatomyositis (DM)FDAFDA approvalintravenous human immunoglobulinIVIgOctagam 10%U.S. Food and Drug Administration (FDA)

ACR Responds to 2022 Medicare Physician Fee Schedule Proposed Rule

From the College  |  September 14, 2021

Rheumatology leaders are encouraged by continued implementation of E/M coding changes, telehealth flexibilities and rheumatology-specific MIPS Value Pathway, but have concerns regarding conversion factor reductions and the CMS EHR interoperability and digital quality measures proposal.

Filed under:From the CollegePractice SupportProfessional Topics Tagged with:American College of Rheumatology (ACR)feeMedicareMedicare Physician Fee Schedule (MPFS)telehealthtelemedicine

Vasculitis Guidelines in Focus, Part 3: EGPA

Michael Putman, MD  |  September 14, 2021

In this third article in the series, we talk with Philip Seo, MD, MHS, about eosinophilic granulomatosis with polyangiitis (EGPA).

Filed under:Clinical Criteria/GuidelinesConditionsVasculitis Tagged with:AAV FocusRheumEGPAeosinophilic granulomatosis with polyangiitis (EGPA)guidelineVasculitis

Rheum After 5: Dr. David Isenberg, Rheumatologist & Bandleader

Carol Patton  |  September 14, 2021

In 2015, the Department of Immunology at the University College London (UCL) rented a room above the King & Queen pub in London for a seminar series. Among the speakers was David Isenberg, MD, FRCP (Fellow of the Royal College of Physicians), FAMS (Fellow of the Academy of Medical Sciences), who still serves as UCL’s academic…

Filed under:AudioRheum After 5 Tagged with:Dr. David Isenberg

Summer 2021’s Awards, Appointments & Announcements in Rheumatology

Kelly April Tyrrell & Gretchen Henkel  |  September 14, 2021

Marian Hannan Celebrated after 10 Years as AC&R Editor-in-Chief By Kelly April Tyrrell This summer, the 10-year tenure of Marian Hannan, MPH, DSc, as editor in chief of Arthritis Care & Research (AC&R), has come to an end. Kelli Allen, PhD, assumed the post on July 1. “Marian has done a fantastic job over the…

Filed under:AwardsProfiles Tagged with:Dr. John J. O’SheaDr. Marian HannanDr. Tuhina Neogi

COVID-19 & Pediatric Rheumatology

Elizabeth Sloan, MD  |  September 14, 2021

PRSYM 2021—Although primary COVID-19 infection has the most significant complications in adult patients, pediatric rheumatologists have also seen significant changes in their practice over the past year. With the emergence of COVID-19, the rise of a mysterious post-COVID hyper­inflammatory syndrome, now known as multisystem inflammatory syndrome in children (MIS-C), was identified, and pediatric rheumatologists have…

Filed under:ConditionsPediatric Conditions Tagged with:COVID-19Multisystem Inflammatory Syndrome in Children (MIS-C)PRSYM

Case Report: Sarcoidosis in Patient with History of IgG4-Related Disease

Veronica Matto, DO, Rajshri Shah, MD, Jie Ouyang, MD, PhD, Cory Perugino, DO, & Joseph J. LaConti, MD, PhD  |  September 14, 2021

Sarcoidosis and IgG4-related disease (IgG4-RD) are both immune-mediated, often multi-organ, diseases of uncertain etiology capable of presenting with diverse clinical manifestations. Many clinical features are common to both conditions, including hypergammaglobulinemia, the ability to form inflammatory masses and involvement of the lymph nodes, lacrimal glands, salivary glands, meninges and lungs. Although imaging modalities, such as…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:IgG4 related diseaseSarcoidosis

Case Report: A 5-Year-Old with an Ischemic Digit

Marta Michalska-Smith, MD, & Colleen K. Correll, MD, MPH  |  September 14, 2021

Janus kinase 1 and 2 inhibitors (jakinibs) have been approved for the treatment of rheumatoid arthritis, psoriatic arthritis and, most recently, juvenile idiopathic arthritis. They have also shown promise in the treatment of interferon (IFN) mediated diseases. The Janus kinase and signal transducer and activator of transcription (JAK/STAT) pathway is the principal signaling pathway for…

Filed under:Conditions Tagged with:Aicardi-Goutières SyndromeJanus Kinase Inhibitors

Case Report: Drug-Induced Lupus

Haseeb Chaudhary, MD, Prem Parajuli, MD, & Devy Setyono, MD  |  September 14, 2021

The incidence of drug-induced lupus continues to rise as clinicians expand their therapeutic armamentarium. An estimated 15,000–30,000 cases of drug-induced lupus occur every year in the U.S. alone.1 It is a well-known, but rare, complication of commonly used medications, such as anti-hypertensive, anti-arrhythmic and anti-epileptic drugs, as well as biologic and immune checkpoint therapies.2,3 The…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:cardiac tamponadedrug-induced lupusphenytoin

Case Report: Reactive Arthritis Following COVID-19

Samuel C. Purkey, DO, James Z. Drew, MD, & Marcum Collins, MD  |  September 14, 2021

SARS-CoV-2, or COVID-19, is a complex disease entity that continues to evolve. Physicians, researchers and scientists alike have worked tirelessly to tackle this beast in its short existence; however, we are reminded daily that there is more to this virus than meets the eye. It is well known that COVID-19 can cause acute respiratory failure…

Filed under:Conditions Tagged with:COVID-19Reactive arthritisTenosynovitis

  • « Previous Page
  • 1
  • …
  • 63
  • 64
  • 65
  • 66
  • 67
  • …
  • 324
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences